Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Multiple myeloma gammopathies

Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Leukemia volume 32, pages 1803–1807 (2018)Cite this article

Subjects

Despite the progress made in the past two decades, multiple myeloma (MM) remains an incurable disease and the prognosis of patients relapsing after first-generation novel agents is extremely poor [1]. Pomalidomide and carfilzomib, respectively second-generation immunomodulatory drug (IMiD) and proteasome inhibitor (PI), proved to be effective in patients previously exposed to both lenalidomide and bortezomib [2,3,4] and received approval for the treatment of relapsed/refractory MM (RRMM).

Synergism between IMiDs and PIs has been demonstrated [5,6,7]: twice-weekly carfilzomib in combination with pomalidomide and dexamethasone (KPd) was well tolerated and effective in patients refractory to lenalidomide [8].

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–57.

    Article  PubMed  CAS  Google Scholar 

  2. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.

    Article  CAS  Google Scholar 

  3. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31:107–14.

    Article  PubMed  CAS  Google Scholar 

  5. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3. Lancet. 2010;376:2075–85.

    Article  PubMed  CAS  Google Scholar 

  6. Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  7. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.

    Article  PubMed  CAS  Google Scholar 

  8. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284–90.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127:3360–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497–503.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009–02. Blood. 2013;121:1968–75.

    Article  PubMed  CAS  Google Scholar 

  12. Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the patients who participated in the source trials, the nurses Carina Pusceddu and Cristina M. Russo, the data managers Antonella Fiorillo and Jessica Mastrovito, and Ugo Panzani and Giorgio Schirripa for assistance in preparation and submission of the paper.

Author contributions

S.B., R.M., A.P., P.S., and M.B. designed the study and supervised its conduct and the data analysis; S.B., R.M., A.M.C., A.M.L., A.B., G.G., F.P., R.F., L.D.P., G.R., A.L., P.B., and M.B recruited patients in the source studies and provided relevant data; S.B., R.M., R.T. collected, assembled, and analyzed the data; S.S. performed the statistical analysis; S.B. and R.M. drafted the initial manuscript; and all authors were given unrestricted access to the data, critically reviewed the manuscript drafts, approved the final version, and made the decision to submit the manuscript for publication.

Author information

Authors and Affiliations

  1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

    Sara Bringhen, Roberto Mina, Stefano Spada, Rossella Troia, Antonio Palumbo & Mario Boccadoro

  2. Ospedale Niguarda Ca’ Granda, Milan, Italy

    Anna Maria Cafro & Paola Bertazzoni

  3. Università degli Studi di Perugia, Struttura Complessa Universitaria Oncoematologia - Azienda Ospedaliera Santa Maria di Terni, Terni, Italy

    Anna Marina Liberati

  4. SC Ematologia e Dipartimento di Oncologia Clinica, A.O. Spedali Civili, Brescia, Italy

    Angelo Belotti & Giuseppe Rossi

  5. Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy

    Gianluca Gaidano & Lorenzo De Paoli

  6. Clinica Ematologica, Azienda sanitaria Universitaria Integrata, DAMe, Università di Udine, Udine, Italy

    Francesca Patriarca & Renato Fanin

  7. Struttura Complessa Universitaria Oncoematologia - Azienda Ospedaliera Santa Maria di Terni, Terni, Italy

    Alessandra Lombardo

  8. Department of Hematology, Erasmus Medical Center, Rotterdam, Netherlands

    Pieter Sonneveld

Authors
  1. Sara Bringhen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberto Mina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna Maria Cafro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna Marina Liberati
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefano Spada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angelo Belotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gianluca Gaidano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesca Patriarca
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rossella Troia
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Renato Fanin
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lorenzo De Paoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Giuseppe Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Alessandra Lombardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Paola Bertazzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Antonio Palumbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Pieter Sonneveld
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Mario Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sara Bringhen.

Ethics declarations

Conflict of interest

S.B. has received honoraria from Celgene, Janssen, BMS, Amgen; Advisory board for Janssen and Amgen; consultancy fees from Takeda; G.G. has served on the advisory boards for Roche, AbbVie, Janssen, Gilead, and Morphosys; F.P. has received lecturing fees from MSD Italia and served on the advisory board for Janssen; L.D.P. has served on the advisory boards for AbbVie, Amgen, Celgene, and Janssen; G.R. has served on the advisory boards for Celgene and Amgen; A.P. is currently a Takeda employee; P.S. has received research support from Amgen, Celgene, Janssen, Karyopharm, and honoraria from Amgen, Celgene, Janssen, Karyopharm and BMS; and M.B. has received research funding from Amgen, BMS, Celgene, Janssen, Mundipharma, Novartis, Sanofi, and honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Sanofi. The remaining authors declare that they have no conflict of interest.

Additional information

Antonio Palumbo: Currently Takeda employee.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bringhen, S., Mina, R., Cafro, A.M. et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia 32, 1803–1807 (2018). https://doi.org/10.1038/s41375-018-0024-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0024-1

This article is cited by

Search

Advanced search

Quick links